AlgoTx Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series C
- (Cancelled)
- Investors
-
6
AlgoTx General Information
Description
Operator of a biotechnology company intended to develop topical treatments for complex pain. The company directly targets the damaged nerve fibers in the skin and avoids systemic side effects of oral drugs by repurposing existing drugs towards topical pain relief programs that are concerned with the pain of chemotherapy-induced peripheral neuropathy and diabetic neuropathic pain. , enabling medical practitioners to reduce the pain caused to patients due to Chemotherapy-induced Peripheral Neuropathy.
Contact Information
Website
www.algotx.comCorporate Office
- 49 Rue Des Nouvelles
- 92150 Suresnes
- France
Corporate Office
- 49 Rue Des Nouvelles
- 92150 Suresnes
- France
AlgoTx Timeline
AlgoTx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 09-Oct-2024 | Cancelled | Clinical Trials - Phase 2 | |||
| 5. Grant | 09-Mar-2023 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series B) | 01-Mar-2023 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 24-Nov-2020 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 20-Nov-2019 | $2.88M | $3.47M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Jun-2018 | $590K | $590K | Completed | Startup |
AlgoTx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A Shares | ||||||||
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
AlgoTx Comparisons
Industry
Financing
Details
AlgoTx Competitors (6)
One of AlgoTx’s 6 competitors is WinSanTor, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| WinSanTor | Venture Capital-Backed | San Diego, CA | ||||
| Regenacy Pharmaceuticals | Venture Capital-Backed | Waltham, MA | ||||
| Jazz Pharmaceuticals | Formerly VC-backed | Dublin, Ireland | ||||
| ONO Pharmaceutical | Corporation | Osaka, Japan | ||||
| Imbrium Therapeutics | Corporation | Stamford, CT |
AlgoTx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AlgoTx Patents
AlgoTx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230103300-A1 | Topical pharmaceutical composition in gel form comprising at least amitriptyline for use in the treatment of coronavirus-induced neuropathic pain | Inactive | 01-Oct-2021 | ||
| EP-4159195-A1 | Topical pharmaceutical composition in gel form comprising at least amitriptyline for use in the treatment of neuropathic pain induced by a coronavirus | Inactive | 01-Oct-2021 | ||
| US-20230103462-A1 | Topical pharmaceutical composition in gel form comprising at least amitriptyline for use in the treatment of neuropathic phantom limb pain | Inactive | 01-Oct-2021 | ||
| JP-2023053933-A | Topical pharmaceutical composition in gel form comprising at least amitriptyline for use in treatment of neuropathic pain induced by coronavirus | Pending | 01-Oct-2021 | ||
| JP-2023053932-A | Topical pharmaceutical composition in gel form comprising at least amitriptyline for use in treatment of neuropathic phantom limb pain | Pending | 01-Oct-2021 | A61K31/137 |
AlgoTx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AlgoTx Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Majycc Esante Invest | Venture Capital | Minority | ||
| Relyens | Impact Investing | Minority | ||
| Turenne Groupe | PE/Buyout | Minority | ||
| UI Investissement | PE/Buyout | Minority | ||
| Bpifrance | Sovereign Wealth Fund | Minority |
AlgoTx FAQs
-
When was AlgoTx founded?
AlgoTx was founded in 2018.
-
Where is AlgoTx headquartered?
AlgoTx is headquartered in Suresnes, France.
-
What is the size of AlgoTx?
AlgoTx has 6 total employees.
-
What industry is AlgoTx in?
AlgoTx’s primary industry is Drug Discovery.
-
Is AlgoTx a private or public company?
AlgoTx is a Private company.
-
What is AlgoTx’s current revenue?
The current revenue for AlgoTx is .
-
How much funding has AlgoTx raised over time?
AlgoTx has raised $39.1M.
-
Who are AlgoTx’s investors?
Majycc Esante Invest, Relyens, Turenne Groupe, UI Investissement, and Bpifrance are 5 of 6 investors who have invested in AlgoTx.
-
Who are AlgoTx’s competitors?
WinSanTor, Regenacy Pharmaceuticals, Jazz Pharmaceuticals, ONO Pharmaceutical, and Imbrium Therapeutics are some of the 6 competitors of AlgoTx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
